Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
Standard
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. / Halangk, Juliane; Sarrazin, Christoph; Neumann, Konrad; Puhl, Gero; Mueller, Tobias; Teuber, Gerlinde; Klinker, Hartwig; Hinrichsen, Holger; Buggisch, Peter; Landt, Olfert; Weich, Viola; Bergk, Alexandra; Wiedenmann, Bertram; Neuhaus, Peter; Berg, Thomas; Witt, Heiko.
in: J HEPATOL, Jahrgang 49, Nr. 3, 3, 2008, S. 339-345.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
AU - Halangk, Juliane
AU - Sarrazin, Christoph
AU - Neumann, Konrad
AU - Puhl, Gero
AU - Mueller, Tobias
AU - Teuber, Gerlinde
AU - Klinker, Hartwig
AU - Hinrichsen, Holger
AU - Buggisch, Peter
AU - Landt, Olfert
AU - Weich, Viola
AU - Bergk, Alexandra
AU - Wiedenmann, Bertram
AU - Neuhaus, Peter
AU - Berg, Thomas
AU - Witt, Heiko
PY - 2008
Y1 - 2008
N2 - BACKGROUND/AIMS: Intercross studies in inbred mice susceptible or resistant to liver fibrosis revealed complement factor 5 as a quantitative trait gene associated with the development of fibrosis. In 277 patients with hepatitis C, two C5 SNPs, rs17611 and rs2300929, have been associated with advanced fibrosis. METHODS: We investigated the association of these C5 SNPs with advanced fibrosis in 1435 HCV infected patients and in 1003 patients with other liver diseases. We performed genotyping with melting curve analysis using fluorescence resonance energy transfer probes in the LightCycler. RESULTS: The defined high-risk genotypes (AA and TT) and alleles (A and T) were not associated with advanced fibrosis in HCV patients when Chi square testing and logistic regression analysis were applied (rs17611A 0.45 in F0-1 vs. 0.43 in F2-4, P=0.31; rs2300929T 0.91 F0-1 and 0.91 in F2-4, P=0.82). In the group of patients with liver diseases other than HCV we neither found an association of the C5 SNPs with advanced fibrosis nor an overrepresentation of the SNPs in patients with cirrhosis. CONCLUSIONS: We found no evidence that these C5 SNPs are genetic risk factors for the development of advanced fibrosis in chronic HCV infection or other chronic liver diseases.
AB - BACKGROUND/AIMS: Intercross studies in inbred mice susceptible or resistant to liver fibrosis revealed complement factor 5 as a quantitative trait gene associated with the development of fibrosis. In 277 patients with hepatitis C, two C5 SNPs, rs17611 and rs2300929, have been associated with advanced fibrosis. METHODS: We investigated the association of these C5 SNPs with advanced fibrosis in 1435 HCV infected patients and in 1003 patients with other liver diseases. We performed genotyping with melting curve analysis using fluorescence resonance energy transfer probes in the LightCycler. RESULTS: The defined high-risk genotypes (AA and TT) and alleles (A and T) were not associated with advanced fibrosis in HCV patients when Chi square testing and logistic regression analysis were applied (rs17611A 0.45 in F0-1 vs. 0.43 in F2-4, P=0.31; rs2300929T 0.91 F0-1 and 0.91 in F2-4, P=0.82). In the group of patients with liver diseases other than HCV we neither found an association of the C5 SNPs with advanced fibrosis nor an overrepresentation of the SNPs in patients with cirrhosis. CONCLUSIONS: We found no evidence that these C5 SNPs are genetic risk factors for the development of advanced fibrosis in chronic HCV infection or other chronic liver diseases.
M3 - SCORING: Zeitschriftenaufsatz
VL - 49
SP - 339
EP - 345
JO - J HEPATOL
JF - J HEPATOL
SN - 0168-8278
IS - 3
M1 - 3
ER -
